Literature DB >> 2813949

Validation of a vertical visual analogue scale as a measure of clinical dyspnea.

A G Gift.   

Abstract

The purpose of this study was to validate a vertical visual analogue scale (VVAS) as a measure of clinical dyspnea. Concurrent validity was demonstrated by having asthmatics score their dyspnea intensity on both a VVAS and a horizontal visual analogue scale (HVAS), and then measuring their peak expiratory flow rate (PEFR). Correlation between the VVAS and HVAS was r = .97; between the VVAS and the PEFR, correlation was r = -.85, demonstrating the concurrent validity of the VVAS as a measure of dyspnea. Construct validity then was established, using the contrasted-groups approach with repeated measures. Both asthmatics and those with chronic obstructive lung disease (COPD) rated their dyspnea on the VVAS during times of severe and little airway obstruction. The dyspnea ratings at times of severe versus low obstruction were found to be different for both the asthmatic and COPD subjects. The VVAS was shown to have both concurrent and construct validity as a measure of dyspnea.

Entities:  

Mesh:

Year:  1989        PMID: 2813949     DOI: 10.1002/j.2048-7940.1989.tb01129.x

Source DB:  PubMed          Journal:  Rehabil Nurs        ISSN: 0278-4807            Impact factor:   1.625


  34 in total

1.  Comparison of conditional quality of life terminology and visual analogue scale measurements.

Authors:  S M Grunberg; S Groshen; S Steingass; S Zaretsky; B Meyerowitz
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

2.  A Multidimensional Profile of Dyspnea in Hospitalized Patients.

Authors:  Jennifer P Stevens; Andrew R Sheridan; Heather B Bernstein; Kathy Baker; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett
Journal:  Chest       Date:  2019-05-22       Impact factor: 9.410

3.  The shuttle walking test: a reproducible method for evaluating the impact of shortness of breath on functional capacity in patients with advanced cancer.

Authors:  S Booth; L Adams
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

4.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Anil Chauhan; Nikita Jaiswal
Journal:  Cochrane Database Syst Rev       Date:  2020-04-28

5.  Respiratory impact of a grand tour: insight from professional cycling.

Authors:  Hayden Allen; Oliver J Price; Jon Greenwell; James H Hull
Journal:  Eur J Appl Physiol       Date:  2021-01-09       Impact factor: 3.078

Review 6.  Dyspnea: assessment and treatment.

Authors:  M Farncombe
Journal:  Support Care Cancer       Date:  1997-03       Impact factor: 3.603

7.  Lung volume reduction surgery and pulmonary rehabilitation improve exercise capacity and reduce dyspnea during functional activities in people with emphysema.

Authors:  Janna Beling
Journal:  Cardiopulm Phys Ther J       Date:  2009-06

Review 8.  Opioids for chronic refractory breathlessness: right patient, right route?

Authors:  David C Currow; Magnus Ekstrom; Amy P Abernethy
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

Review 9.  Measurement of dyspnoea in chronic obstructive pulmonary disease.

Authors:  E G Eakin; R M Kaplan; A L Ries
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

10.  Additional evidence for the affective dimension of dyspnea in patients with COPD.

Authors:  Virginia Carrieri-Kohlman; DorAnne Donesky-Cuenco; Soo Kyung Park; Lynda Mackin; Huong Q Nguyen; Steven M Paul
Journal:  Res Nurs Health       Date:  2010-02       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.